$103.27
1.56%
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US76243J1051
Symbol
RYTM

Rhythm Pharmaceuticals, Inc. Stock price

$103.27
+15.45 17.59% 1M
+48.61 88.93% 6M
+47.29 84.48% YTD
+59.08 133.70% 1Y
+79.70 338.14% 3Y
+85.03 466.17% 5Y
+73.27 244.23% 10Y
+73.27 244.23% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+1.59 1.56%
ISIN
US76243J1051
Symbol
RYTM
Industry

Key metrics

Basic
Market capitalization
$6.9b
Enterprise Value
$6.7b
Net debt
positive
Cash
$291.0m
Shares outstanding
63.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
43.9 | 36.4
EV/Sales
42.7 | 35.5
EV/FCF
negative
P/B
51.4
Financial Health
Equity Ratio
42.0%
Return on Equity
-160.8%
ROCE
-72.9%
ROIC
-5,544.5%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$156.3m | $188.3m
EBITDA
$-175.9m | $-181.6m
EBIT
$-177.4m | $-173.8m
Net Income
$-188.4m | $-192.8m
Free Cash Flow
$-107.7m
Growth (TTM | estimate)
Revenue
22.3% | 44.7%
EBITDA
56.4% | 31.2%
EBIT
56.2% | 34.5%
Net Income
53.2% | 27.1%
Free Cash Flow
16.2%
Margin (TTM | estimate)
Gross
89.3%
EBITDA
-112.6% | -96.4%
EBIT
-113.5%
Net
-120.6% | -102.4%
Free Cash Flow
-68.9%
More
EPS
$-3.0
FCF per Share
$-1.7
Short interest
8.7%
Employees
283
Rev per Employee
$460.0k
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

19x Buy
95%
1x Hold
5%

Analyst Opinions

20 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
95%
Hold
5%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
156 156
22% 22%
100%
- Direct Costs 17 17
18% 18%
11%
139 139
23% 23%
89%
- Selling and Administrative Expenses 159 159
6% 6%
101%
- Research and Development Expense 158 158
55% 55%
101%
-176 -176
56% 56%
-113%
- Depreciation and Amortization 1.53 1.53
7% 7%
1%
EBIT (Operating Income) EBIT -177 -177
56% 56%
-114%
Net Profit -188 -188
53% 53%
-121%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired hypothalamic obesity –
Positive
The Motley Fool
19 days ago
Rhythm Pharmaceuticals (RYTM -1.85%), a biopharmaceutical company focused on rare genetic diseases related to obesity, reported its Q2 2025 earnings on August 5, 2025. However, the company reported a GAAP net loss per share of ($0.75).
Neutral
Seeking Alpha
19 days ago
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David P. Meeker - Chairman, President & CEO Hunter C.
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 283
Founded 2008
Website rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today